Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

NCT03213626 is registered in ClinicalTrials.gov with Patrick Joseph Loehrer Sr. as lead sponsor.

NCT NCT03213626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Patrick Joseph Loehrer Sr.
Phase
Phase 2
Overall status
Terminated
Start date
October 13, 2017
Completion date
November 18, 2019
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma metastatic